EP2967081A4 - Modified caspase polypeptides and uses thereof - Google Patents

Modified caspase polypeptides and uses thereof Download PDF

Info

Publication number
EP2967081A4
EP2967081A4 EP14778378.1A EP14778378A EP2967081A4 EP 2967081 A4 EP2967081 A4 EP 2967081A4 EP 14778378 A EP14778378 A EP 14778378A EP 2967081 A4 EP2967081 A4 EP 2967081A4
Authority
EP
European Patent Office
Prior art keywords
uses
modified caspase
caspase polypeptides
polypeptides
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14778378.1A
Other languages
German (de)
French (fr)
Other versions
EP2967081A2 (en
EP2967081B1 (en
Inventor
David Spencer
Wei-Chun Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BELLICUM PHARMACEUTICALS Inc
Original Assignee
BELLICUM PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13/792,135 priority Critical patent/US9434935B2/en
Application filed by BELLICUM PHARMACEUTICALS Inc filed Critical BELLICUM PHARMACEUTICALS Inc
Priority to PCT/US2014/022004 priority patent/WO2014164348A2/en
Publication of EP2967081A2 publication Critical patent/EP2967081A2/en
Publication of EP2967081A4 publication Critical patent/EP2967081A4/en
Application granted granted Critical
Publication of EP2967081B1 publication Critical patent/EP2967081B1/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472Cysteine endopeptidases (3.4.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52Isomerases (5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90Isomerases (5.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22Cysteine endopeptidases (3.4.22)
    • C12Y304/22062Caspase-9 (3.4.22.62)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y502/00Cis-trans-isomerases (5.2)
    • C12Y502/01Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
EP14778378.1A 2013-03-10 2014-03-07 Modified caspase polypeptides and uses thereof Active EP2967081B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/792,135 US9434935B2 (en) 2013-03-10 2013-03-10 Modified caspase polypeptides and uses thereof
PCT/US2014/022004 WO2014164348A2 (en) 2013-03-10 2014-03-07 Modified caspase polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
EP2967081A2 EP2967081A2 (en) 2016-01-20
EP2967081A4 true EP2967081A4 (en) 2017-01-04
EP2967081B1 EP2967081B1 (en) 2019-07-03

Family

ID=51488078

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14778378.1A Active EP2967081B1 (en) 2013-03-10 2014-03-07 Modified caspase polypeptides and uses thereof

Country Status (6)

Country Link
US (3) US9434935B2 (en)
EP (1) EP2967081B1 (en)
JP (2) JP6537984B2 (en)
AU (2) AU2014249417B2 (en)
CA (1) CA2903216A1 (en)
WO (1) WO2014164348A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
US10238690B2 (en) 2013-03-15 2019-03-26 Celgene Corporation Modified T lymphocytes comprising an inducible caspase and methods of apoptosis
WO2014197638A2 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
AU2015226960A1 (en) * 2014-03-07 2016-09-15 Bellicum Pharmaceuticals, Inc. Caspase polypeptides having modified activity and uses thereof
KR20160135233A (en) 2014-04-07 2016-11-25 노파르티스 아게 Treatment of cancer using anti-cd19 chimeric antigen receptor
JP2018501463A (en) 2014-10-08 2018-01-18 ノバルティス アーゲー Biomarker for predicting therapeutic response to chimeric antigen receptor therapy and use thereof
CA2966300A1 (en) 2014-11-03 2016-05-12 Leiden University Medical Center T cell receptors directed against bob1 and uses thereof
US20160166613A1 (en) * 2014-12-15 2016-06-16 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
AU2015362753A1 (en) 2014-12-15 2017-04-27 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
MX2017012939A (en) 2015-04-08 2018-05-22 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell.
JP2018516592A (en) 2015-04-17 2018-06-28 デイビッド・マクスウエル・バレットDavid Maxwell BARRETT Methods for improving efficacy and proliferation of chimeric antigen receptor expressing cells
JP2018519842A (en) 2015-07-21 2018-07-26 ノバルティス アーゲー Methods for improving the effectiveness and expansion of immune cells
US20180252727A1 (en) 2015-09-03 2018-09-06 Mayo Foundation For Medical Education And Research Biomarkers predictive of cytokine release syndrome
WO2017044464A1 (en) * 2015-09-11 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Biologically relevant orthogonal cytokine/receptor pairs
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CA3039646A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
WO2018208849A1 (en) 2017-05-09 2018-11-15 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
WO2019084288A1 (en) 2017-10-25 2019-05-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2019089844A1 (en) 2017-11-01 2019-05-09 Allogene Therapeutics, Inc. Modified caspase-9 polypeptides and methods of use thereof
WO2019113509A2 (en) 2017-12-08 2019-06-13 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining car-t cell efficacy
WO2019126344A1 (en) 2017-12-20 2019-06-27 Bellicum Pharmaceuticals, Inc. Multimeric piperidine derivatives
WO2019169290A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
FR2610631B1 (en) 1987-02-09 1989-11-24 Pasteur Institut Molecules comprising at least one peptide sequence bearing one or more, epitope characteristic of a protein produced by p. falciparum in hepatocytes, and their uses, particularly for malaria diagnosis or vaccine compositions against malaria
US5869608A (en) 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
EP0510691B1 (en) 1991-04-26 2004-11-03 Osaka Bioscience Institute DNA coding for human cell surface antigen
US5780036A (en) 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
DE4228457A1 (en) 1992-08-27 1994-04-28 Beiersdorf Ag Preparation of heterodimeric PDGF-AB with the aid of a bicistronic vector system in mammalian cells
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
CN1119876A (en) 1993-02-12 1996-04-03 莱兰斯坦福初级大学评议会 Regulated transcription of targeted genes and other biological events
US5426027A (en) 1993-05-20 1995-06-20 The Government Of The United States Of America As Represented By The Secretary Nucleic acid probes and methods for detecting Candida DNA cells in blood
US5648226A (en) 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
EP0721341A4 (en) 1993-08-06 1998-04-22 Cytel Corp Cloning and characterization of the complete mage-1 gene
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
FR2722208B1 (en) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med New internal site of ribosome entry vector containing the therapeutic use and
EP0785992A4 (en) 1994-10-25 1999-12-22 Univ Leland Stanford Junior Conditional transformation of genetically engineered cells
US5741899A (en) 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6010878A (en) * 1996-05-20 2000-01-04 Smithkline Beecham Corporation Interleukin-1 β converting enzyme like apoptotic protease-6
NZ333607A (en) 1996-07-10 2000-08-25 Immunex Corp Method of stimulating the immune system by transfecting dendritic cells
US5955596A (en) 1996-07-26 1999-09-21 American Cyanamid Company NucA protein of Haemophilus influenzae and the gene encoding that protein
US6046158A (en) 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US5965242A (en) 1997-02-19 1999-10-12 Eastman Kodak Company Glow-in-the-dark medium and method of making
US6403765B1 (en) 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
EP1254953A4 (en) 1999-12-28 2004-06-02 Toyoshima Kumao Maturation-promoting agent for immature dendritic cells
US7435585B2 (en) 2000-01-03 2008-10-14 University Of Pennsylvania Auto-stimulating cells and methods for making and using the same
SE0001642D0 (en) 2000-05-04 2000-05-04 Sahltech Ab Reagent for the detection of biomolecules, and use thereof
US20030232055A1 (en) 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
AU8125201A (en) 2000-08-10 2002-02-18 Univ Texas The tumor suppressor car-1
US20020160975A1 (en) 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
AU2178002A (en) 2000-10-31 2002-05-15 Hoffmann La Roche Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
DE60140074D1 (en) 2000-12-14 2009-11-12 Burnham Inst Non-apoptotic forms of cell death and method of modulation
AU2002354560A1 (en) 2001-07-09 2003-01-29 Oklahoma Medical Research Foundation Targeted fusion proteins and methods for the characterization of cellular membrane domains
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003035003A2 (en) 2001-10-26 2003-05-01 Cleveland Clinic Foundation Fused cells, methods of forming same, and therapie utilizing same
EP2933334B1 (en) 2003-02-18 2019-09-18 Baylor College of Medicine Induced activation in dendritic cells
WO2007050095A2 (en) 2004-11-19 2007-05-03 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
AU2006203850A1 (en) 2006-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
WO2006133398A2 (en) 2005-06-08 2006-12-14 Invitrogen Corporation In vitro activated donor t-cells to promote transplant engraftment
KR100705981B1 (en) 2005-10-12 2007-04-04 주식회사 리제론 Compositions comprising human growth hormone for preventing hair loss or stimulating hair sprouting
US20080300202A1 (en) 2006-05-18 2008-12-04 The State of Oregon acting by and through the State Board of Higher Education on behalf of the Subtractive transgenics
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US20120328628A1 (en) 2006-07-07 2012-12-27 The Regents Of The University Of California Antibodies to conformationally trapped proteins
CA3058450A1 (en) 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
AU2008236629B2 (en) 2007-04-07 2014-03-06 Whitehead Institute For Biomedical Research Reprogramming of somatic cells
JP2008307007A (en) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
EP2006376A1 (en) * 2007-06-21 2008-12-24 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof
DK2224954T3 (en) 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
US8114968B2 (en) 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
CA2738031A1 (en) 2008-09-22 2010-03-25 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
WO2011035018A2 (en) 2009-09-18 2011-03-24 Fate Therapeutics, Inc. Suicide ready cells
WO2011130566A2 (en) 2010-04-16 2011-10-20 Bellicum Pharmaceuticals, Inc. Method for treating solid tumors
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2013040371A2 (en) 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
WO2014197638A2 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
AU2015226960A1 (en) 2014-03-07 2016-09-15 Bellicum Pharmaceuticals, Inc. Caspase polypeptides having modified activity and uses thereof
CA2959168A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
US20160166613A1 (en) 2014-12-15 2016-06-16 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
AU2015362753A1 (en) 2014-12-15 2017-04-27 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KARIN C STRAATHOF ET AL: "A inducible caspase 9 safety switch for T-cell therapy", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 105, no. 11, 1 June 2005 (2005-06-01), pages 4247 - 4254, XP008126232, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2004-11-4564 *
See also references of WO2014164348A2 *

Also Published As

Publication number Publication date
JP2018171075A (en) 2018-11-08
AU2014249417B2 (en) 2017-07-13
US20180251746A1 (en) 2018-09-06
WO2014164348A2 (en) 2014-10-09
EP2967081B1 (en) 2019-07-03
US9932572B2 (en) 2018-04-03
AU2017232045A1 (en) 2017-10-05
US20140255360A1 (en) 2014-09-11
US20170015987A1 (en) 2017-01-19
JP6537984B2 (en) 2019-07-03
JP2016514960A (en) 2016-05-26
CA2903216A1 (en) 2014-10-09
US9434935B2 (en) 2016-09-06
AU2014249417A1 (en) 2015-09-17
EP2967081A2 (en) 2016-01-20
WO2014164348A3 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
EP3025635A4 (en) Manipulator and manipulator system
EP2983600A4 (en) Medical systems and methods
EP3052511A4 (en) Polynucleotide molecules and uses thereof
EP2968259A4 (en) Bioactive concentrates and uses thereof
EP3052479A4 (en) Polynucleotide molecules and uses thereof
EP2992097A4 (en) Compositions and methods
EP3026062A4 (en) Anti-pd-1 antibody and use thereof
EP2997520A4 (en) Operations monitoring in an area
EP2976706A4 (en) Advanced authentication techniques and applications
IL246287D0 (en) Fabs-in-tandem immunoglobulin and uses thereof
EP2951283A4 (en) Compositions and methods
EP2993996A4 (en) Juicing systems and methods
SG11201507214SA (en) Pyrrolobenzodiazepines and conjugates thereof
SI2958944T1 (en) Antidll3-antibody-pbd conjugates and uses thereof
EP3060119A4 (en) Sensors and applications
GB201317982D0 (en) Pyrrolobenzodiazepines and conjugates thereof
HK1220467A1 (en) Anti-il-33 antibodies and uses thereof -il-33
HK1219651A1 (en) Pyrrolobenzodiazepines and conjugates thereof
HK1226056A1 (en) Pyrazolo compounds and uses thereof
EP2996638A4 (en) Intervertebral devices and related methods
HK1214140A1 (en) Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) Pyrrolobenzodiazepines and conjugates thereof
IL240393D0 (en) Il-33 antagonists and uses thereof
EP3027204A4 (en) Multipartite signaling proteins and uses thereof
DK3043784T3 (en) Aryletes and uses thereof

Legal Events

Date Code Title Description
AX Request for extension of the european patent to:

Extension state: BA ME

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

17P Request for examination filed

Effective date: 20151012

DAX Request for extension of the european patent (to any country) (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHANG, WEI-CHUN

Inventor name: SPENCER, DAVID

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SPENCER, DAVID

Inventor name: CHANG, WEI-CHUN

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4545 20060101ALI20161130BHEP

Ipc: A01N 65/00 20090101AFI20161130BHEP

Ipc: C12N 5/00 20060101ALI20161130BHEP

Ipc: C12P 21/00 20060101ALI20161130BHEP

Ipc: C12N 9/64 20060101ALI20161130BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20161206

17Q First examination report despatched

Effective date: 20171018

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602014049519

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A01N0065000000

Ipc: A61K0038480000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4545 20060101ALI20180306BHEP

Ipc: A61K 38/52 20060101ALI20180306BHEP

Ipc: C12N 9/90 20060101ALI20180306BHEP

Ipc: A61K 38/48 20060101AFI20180306BHEP

Ipc: C12N 9/64 20060101ALI20180306BHEP

INTG Intention to grant announced

Effective date: 20180430

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20181130

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20190522

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1150165

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014049519

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190703

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D